Ligand ID: 7V7


Drugbank ID:
DB00813
(Fentanyl)


Indication:
For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.

Get human targets for 7V7 in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND '7V7' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL B  73
PRO B  81
TYR B 113
ALA B 135
GLY B  70
1.75A23.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 396
VAL A 398
ALA A 379
PRO A 323
ALA A 382
1.76A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 241
VAL A 182
TYR A 286
ALA A 250
GLY A 179
1.72A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
LEU B 117
SER A 384
ALA A 400
ALA A 399
GLY A 385
1.53A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 396
VAL A 398
ALA A 383
PRO A 323
ALA A 382
1.53A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 396
VAL A 398
ALA A 383
PRO A 323
ALA A 382
1.58A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 396
VAL A 398
ALA A 379
PRO A 323
ALA A 382
1.72A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 207
SER A 709
ALA A  43
TYR A 732
GLY A  44
1.71A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU B 270
PHE B 194
SER B 205
VAL B 193
ALA B 222
1.64A9.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU B 270
PHE B 194
SER B 205
VAL B 193
ALA B 222
1.59A9.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 270
PHE C 194
SER C 205
VAL C 193
ALA C 222
1.56A9.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
VAL D  72
PRO D  80
TYR D 112
ALA D 134
GLY D  69
1.76A20.73
None
GOL  D 204 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
THR C  76
TYR B 172
THR B  57
ARG B 107
1.56A20.73
GOL  C 203 (-4.7A)
None
None
MES  B 203 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6w02 NSP3
(SARS-CoV-2)		5 / 12
LEU A 164
ALA A 134
TYR A 113
ALA A 129
GLY A 130
1.35A22.05
None
None
None
APR  A 201 (-3.6A)
APR  A 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6w4h NSP16
(SARS-CoV-2)		5 / 12
PHE A6947
ALA A6877
TYR A6845
ALA A6870
GLY A6871
1.50A20.34
ACT  A7104 (-3.8A)
None
SAM  A7102 (-4.5A)
None
SAM  A7102 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6w75 NSP16
(SARS-CoV-2)		5 / 12
PHE A6947
ALA A6877
TYR A6845
ALA A6870
GLY A6871
1.49A18.85
SAM  A7102 ( 4.8A)
None
SAM  A7102 ( 4.5A)
None
SAM  A7102 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6w75 NSP16
(SARS-CoV-2)		5 / 12
PHE C6947
ALA C6877
TYR C6845
ALA C6870
GLY C6871
1.49A18.85
FMT  C7115 ( 3.5A)
None
SAM  C7105 ( 4.5A)
None
SAM  C7105 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TRP A 330
THR A 332
ARG B 319
GLN A 281
1.75A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
THR F 332
TYR F 333
THR F 334
ARG F 319
1.71A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TRP B 330
THR B 332
ARG A 319
GLN B 281
1.79A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
THR A 332
TYR A 333
THR A 334
ARG A 319
1.73A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
THR D 332
TYR D 333
THR D 334
ARG D 319
1.72A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TRP B 330
THR B 332
ARG A 319
GLN B 281
1.70A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
THR F 332
TYR F 333
THR F 334
ARG F 319
1.74A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
THR A 332
TYR A 333
THR A 334
ARG A 319
1.71A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
THR A 332
TYR A 333
THR A 334
ARG A 319
1.69A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
THR F 332
TYR F 333
THR F 334
ARG F 319
1.72A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6947
ALA A6877
TYR A6845
ALA A6870
GLY A6871
1.49A20.34
SAH  A7102 (-4.7A)
None
SAH  A7102 (-4.6A)
None
SAH  A7102 (-4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE C6947
ALA C6877
TYR C6845
ALA C6870
GLY C6871
1.49A20.34
SAH  C7102 (-4.6A)
None
SAH  C7102 (-4.6A)
None
SAH  C7102 (-4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE C6947
ALA C6877
TYR C6845
ALA C6870
GLY C6871
1.51A20.34
SAH  C7102 (-4.6A)
None
SAH  C7102 (-4.6A)
None
SAH  C7102 (-4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6947
ALA A6877
TYR A6845
ALA A6870
GLY A6871
1.48A20.34
SAH  A7102 (-4.7A)
None
SAH  A7102 (-4.6A)
None
SAH  A7102 (-4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL D  72
PRO D  80
TYR D 112
ALA D 134
GLY D  69
1.75A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL D  72
PRO D  80
TYR D 112
ALA D 134
GLY D  69
1.74A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL B  72
PRO B  80
TYR B 112
ALA B 134
GLY B  69
1.79A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL C  72
PRO C  80
TYR C 112
ALA C 134
GLY C  69
1.74A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL B  72
PRO B  80
TYR B 112
ALA B 134
GLY B  69
1.78A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
SER A  51
ALA A 119
PRO A  73
TRP A 132
GLY A 116
1.73A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL C  72
PRO C  80
TYR C 112
ALA C 134
GLY C  69
1.74A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL A  72
PRO A  80
TYR A 112
ALA A 134
GLY A  69
1.77A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
VAL A  72
PRO A  80
TYR A 112
ALA A 134
GLY A  69
1.76A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE C6947
ALA C6877
TYR C6845
ALA C6870
GLY C6871
1.48A20.34
FMT  C7105 ( 3.5A)
None
SFG  C7103 ( 4.5A)
None
SFG  C7103 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE A6947
ALA A6877
TYR A6845
ALA A6870
GLY A6871
1.48A20.34
SFG  A7103 ( 4.8A)
None
SFG  A7103 ( 4.6A)
None
SFG  A7103 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE A6947
ALA A6877
TYR A6845
ALA A6870
GLY A6871
1.47A20.34
SFG  A7103 ( 4.8A)
None
SFG  A7103 ( 4.6A)
None
SFG  A7103 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE C6947
ALA C6877
TYR C6845
ALA C6870
GLY C6871
1.46A20.34
FMT  C7105 ( 3.5A)
None
SFG  C7103 ( 4.5A)
None
SFG  C7103 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
THR A 193
TYR A 194
THR A 196
GLN A 197
1.72A20.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
THR B 193
TYR B 194
THR B 196
GLN B 197
1.73A20.41
EDO  B 404 (-4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL B 100
ALA B 129
PRO A  74
ALA B 134
GLY B 133
1.67A21.72
None
APR  B 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU A 160
PHE A 156
ALA A 134
ALA A 129
GLY A 130
1.77A21.72
None
APR  A 201 (-4.7A)
None
APR  A 201 (-3.7A)
APR  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU C 160
PHE C 156
ALA C 134
ALA C 129
GLY C 130
1.75A21.72
None
APR  C 201 (-4.7A)
None
APR  C 201 (-3.7A)
APR  C 201 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU D  75
SER D 128
VAL D  96
ALA D  50
ALA D  39
1.80A21.72
None
APR  D 201 (-4.3A)
None
APR  D 201 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU D 160
PHE D 156
ALA D 134
ALA D 129
GLY D 130
1.80A21.72
None
APR  D 201 (-4.5A)
None
APR  D 201 (-3.7A)
APR  D 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU B 160
PHE B 156
ALA B 134
ALA B 129
GLY B 130
1.79A21.72
None
APR  B 201 (-4.6A)
None
APR  B 201 (-3.7A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_2
(ENDO-1,4-BETA-XYLANA
SE A)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
ARG A7030
PRO A7034
TYR A6828
1.79A20.34
None
None
GTA  A7102 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6947
ALA A6877
TYR A6845
ALA A6870
GLY A6871
1.53A20.34
SAH  A7101 ( 4.8A)
None
SAH  A7101 (-4.5A)
None
SAH  A7101 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
THR A 291
TYR A 283
THR A 277
GLN A 122
1.66A20.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA E 411
PRO L 101
TRP H  33
TYR L  31
GLY E 413
1.63A23.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
SER E 383
TRP H  33
TYR L 102
TYR L  42
GLY H  99
1.48A23.08
DMS  L1601 (-3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA E 411
PRO L 101
TRP H  33
TYR L  31
GLY E 413
1.59A23.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6ym0 HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
SER E 383
TRP H  33
TYR L 102
TYR L  42
GLY H  99
1.50A23.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6ym0 HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA E 411
PRO L 101
TRP H  33
TYR L  31
GLY E 413
1.50A23.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6ym0 HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA E 411
PRO L 101
TRP H  33
TYR L  31
GLY E 413
1.52A23.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA A 411
PRO C 101
TRP B  33
TYR C  31
GLY A 413
1.63A22.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA E 411
PRO L 101
TRP H  33
TYR L  31
GLY E 413
1.59A22.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
SER E 383
TRP H  33
TYR L 102
TYR L  42
GLY H  99
1.47A22.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_A_7V7A202_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA E 411
PRO L 101
TRP H  33
TYR L  31
GLY E 413
1.63A22.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ALA A 411
PRO C 101
TRP B  33
TYR C  31
GLY A 413
1.59A22.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_C_7V7C201_1
(ENDO-1,4-BETA-XYLANA
SE A)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
SER A 383
TRP B  33
TYR C 102
TYR C  42
GLY B  99
1.47A22.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 241
VAL A 182
TYR A 286
ALA A 250
GLY A 179
1.66A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
LEU B 117
SER A 384
ALA A 400
ALA A 399
GLY A 385
1.52A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 12
LEU B 117
SER A 384
ALA A 400
ALA A 399
GLY A 385
1.58A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 207
SER A 709
ALA A  43
TYR A 732
GLY A  44
1.78A11.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TZO_B_7V7B201_1
(ENDO-1,4-BETA-XYLANA
SE A)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 12
LEU B 117
SER A 384
ALA A 400
ALA A 399
GLY A 385
1.55A22.03
None